Cargando…
Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model
PURPOSE: To evaluate the molecular, pharmacokinetic, and pharmacological properties of three anti-vascular endothelial growth factor (VEGF) agents—aflibercept, brolucizumab, and ranibizumab—and to provide a prediction of the optimal design of an intravitreal VEGF challenge in rabbits to assess the p...
Autores principales: | Schubert, William, Terjung, Carsten, Rafique, Ashique, Romano, Carmelo, Ellinger, Philipp, Rittenhouse, Kay D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617509/ https://www.ncbi.nlm.nih.gov/pubmed/36282118 http://dx.doi.org/10.1167/tvst.11.10.36 |
Ejemplares similares
-
Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model
por: Lange, Claudia, et al.
Publicado: (2023) -
Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model
por: Lange, Claudia, et al.
Publicado: (2023) -
Choroidal Vein Alterations in Pachychoroid Disease With Choroidal Vascular Hyperpermeability: Evaluated by Wide-Field Indocyanine Green Angiography
por: He, Guiqin, et al.
Publicado: (2023) -
Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy
por: McAllister, Ian L, et al.
Publicado: (2021) -
Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)